AmarapurkarD.N., DhawanP., KalroR.H.Role of routine estimation of creatinine clearance in patients with liver cirrhosis. Indian J Gastroenterol1994; 13: 79–82.
2.
ArroyoV., GinèsP., GerbesA.L.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology1996; 23: 164–76.
DemirtasS., BozbasA., AkbayA.Diagnostic value of cystatin C for evaluation of hepatorenal sindrome. Clin Chim Acta2001; 311: 81–9.
5.
PapperS.The hepatorenal syndrome. In: EpsteinM., ed. The kidney in liver disease.2nd edition. New York: Elsevier Biomedical, 1983; pp. 87–106.
6.
ArroyoV., ColmeneroJ.Ascites and hepatorenal syndrome in cirrhosis: Pathophysiological basis of therapy and current management. J Hepatol2003; 38(suppl): S69–89.
7.
BernardiM., TrevisaniF.Systemic and regional hemodynamics in preascitic cirrhosis. J Hepatol1997; 27: 588–91.
8.
PlattJ.F., EllisJ.H., RubinJ.M.Renal duplex Doppler ultrasonography: A noninvasive predictor of kidney dysfunction and hepatorenal failure in liver patients. Hepatology1994; 20: 362–9.
GuarnerC., SorianoG., TomasA.Increased serum nitrite and nitrate levels in patients with cirrhosis: Relationship to endotoxemia. Hepatology1993; 18: 1139–43.
11.
WongF., BlendisL.New challenge of hepatorenal syndrome: Prevention and treatment. Hepatology2001; 34: 1242–51.
12.
SheronN., BirdG., GokaJ.Elevated plasma interleukin 6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunol1991; 84: 449–53.
13.
LaffiG., La VillaG., PinzaniM.Altered renal and platelet arachidonic acid metabolism in cirrhosis. Gastroenterology1986; 90: 274–82.
14.
GovindarajanS., NastC.C., SmithW.L.Immunohistochemical distribution of renal prostaglandin endoperoxidase synthase in the hepatorenal syndrome. Hepatology1987; 7: 654–9.
15.
BoyerT., ZiaP., ReynoldsT.Effect of indomethacin and prostaglandin A on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology1979; 77: 215–22.
16.
PakJ.M., LeeS.S.Review: Glucagon in portal hypertension. J Hepatol1994; 20: 825–32.
HoltS., MarleyR., FernandoB.Acute cholestasis-induced renal failure: Effects of antioxidants and ligands for the thromboxane A2 receptor. Kidney Int1999; 55: 271–7.
19.
KostrevaD., CastanerA., KampineJ.Reflex effects of hepatic baroreceptors on renal and cardiac sympathetic nerve activity. Am J Physiol1980; 238: R390–394.
20.
GentiliniP., RomanelliR.G., La VillaG.Effects of low-dose captpril on renal hemodynamics and function in patients with cirrhosis of the liver. Gastroenterology1993; 104: 588–94.
21.
SchepkeM., WernerE., BieckerE.Hemodynamic effects of the angiotensin II receptor antagonist irbesartan in patients with cirrhosis and portal hypertension. Gastroenterolgy2001; 121: 389–95.
22.
SantoroA., ManciniE.Bilirubina ed acidi biliari: tossicità e rimozione. In: Aferesi terapeutica.Editoriale Bios2003: 179–92.
23.
AkriviadisE., BotlaR., BriggsW.Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: A doubleblind, placebo-controlled trial. Gastroenterology2000; 119: 1637–48.
SortP., NavasaM., ArroyoV.Effects of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med1999; 341: 403–9.
26.
TepelM., Van Der GierM., SchwarzfeldC.Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med2000; 343: 180–4.
27.
OrtegaR., GinèsP., UrizJ.Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology2002; 36: 941–8.
28.
ColleI., DurandF., PessioneF.Liver cirrhosis and type I hepatorenal sindrome. J Gastroenterol Hepatol2002; 17: 882–8.
29.
AngeliP., VolpinR., GerundaG.Reversal of type I hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology1999; 29: 1690–7.
30.
FeveryJ., Van CutsemE., NevensF.Reversal of hepatorenal syndrome in four patients by peroral misoprostol (prostalandin E1 analogue) and albumin administration. J Hepatol1990; 11: 153–8.
31.
HoltS., GoodierD., MarleyR.Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet1999; 353: 294–5.
32.
ArroyoV., GinèsP., PlanasR., PanèsJ., RodésJ.Management of patients with cirrhosis and ascites. Semin Liver Dis1986; 6: 353–69.
33.
UritzJ., GinèsP., CordenasA.Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol2000; 33: 43–8.
34.
WilkinsonS.P., WestonM.J., ParsonV., WilliamsR.Dialysis in the treatment of renal failure in patients with liver disease. Clin Nephrol1977; 8: 287–92.
35.
SchifflH., LanfS.M., FischerR.Daily hemodialysis and the outcome of acute renal failure. N Engl J Med2002; 5: 305–10.
36.
BomzonA., RosembergM., GaliD.Systemic hypotension and decreased pressor response in dogs with chronic bile duct ligation. Hepatology1986; 6: 595–600.
37.
SantoroA., ManciniE., SoriceM., FaenzaS.Plasma separation and bilirubin adsorption in patients with excessive hyperbilirubinemia and renal failure before and after liver transplantation. J Am Soc Nephrol2001; 12: 180.
38.
NovelliG., RossiM., PretagostiniR.MARS (Molecular Adsorbent Recirculating System): Experience in 34 cases of acute liver failure. Liver2002; 22(suppl 2): S43–7.
39.
Di CampliC., GaspariR., MignaiG.Successful MARS treatment in severe cholestatic patients with acute on chronic liver failure. Artif Organs2003; 27: 565–9.
40.
RifaiK., ErnstT., KretschmerU.Prometheus - a new extracorporeal system for the treatment of liver failure. J Hepatol2003; 39: 984–90.
41.
GonwaT.A., KlintmalmG.B., LevyM.Impact of pretransplant renal function on survival after liver transplantation. Transplantation1995; 59: 361–5.
42.
NairS., VermaS., ThuluvathP.J.Pretransplant renal function predicts survival in patients undergoing orthotopic liver transplantation. Hepatology2002; 35: 1179–85.
